V
VIRO
vs
O
OMX Copenhagen 25
Over the past 12 months, VIRO has significantly outperformed OMX Copenhagen 25, delivering a return of +102% compared to the OMX Copenhagen 25's 13% drop.
Stocks Performance
VIRO vs OMX Copenhagen 25
Performance Gap
VIRO vs OMX Copenhagen 25
Performance By Year
VIRO vs OMX Copenhagen 25
ViroGates A/S
Glance View
ViroGates A/S develops and markets prognostic products for the healthcare sector. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.